Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novelos Therapeutics has announced positive interim results from an ongoing Medical University of South Carolina Hollings Cancer Center Phase II trial of neoadjuvant treatment with NOV-002 in combination with chemotherapy in patients with stage II-IIIC HER-2/neu negative invasive breast cancer.
Subscribe to our email newsletter
The primary objective of this open-label, single-arm trial is to determine if preoperative administration of NOV-002 in combination with eight cycles of chemotherapy (four of doxorubicin and cyclophosphamide followed by four of docetaxel) results in an appreciably higher pathologic complete response (pCR) rate than expected with this same chemotherapeutic regimen alone. According to the Simon two-stage trial design, if four or more pCRs are observed in the first stage of the trial (19 women), enrollment would continue into the second stage, for a total of 46 women.
To date, 16 women have been enrolled with four pCRs already demonstrated in the first eight women that have both completed chemotherapy and undergone surgery. Furthermore, NOV-002 was associated with decreased hematologic toxicities and with decreased use of growth factors relative to historical experience. Full enrollment of 46 patients is expected mid-2009, with trial conclusion in early 2010.